Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Endoscopic Valve Ablation for Posterior Urethral Valves (PUV)
Treatment for Urogenital congenital anomalies
Effectiveness
90%
Safety Score
65%
Clinical Trials
250
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate relief of obstruction, renal function improvement over months
Treatment Duration
Single endoscopic procedure, lifelong follow-up for renal/bladder function
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$11,111
Comparison vs Catheter Diversion / No Ablation
Cost Difference
$0/year
Same cost
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Endoscopic Valve Ablation for Posterior Urethral Valves (PUV) Outcomes
for Urogenital congenital anomalies
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Common Side Effects
Urethral stricture/scarring
+10%
Bladder dysfunction (neurogenic-like)
+30%
Persistent vesicoureteral reflux
+25%
Urinary tract infection
+3%
Failure to completely ablate valves (requiring repeat)
+8%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov